TG Therapeutics Q3 2026 Revenue Tops Estimates at $259.9M, but EPS Misses at $0.35

TG Therapeutics (TGTX) posted mixed third-quarter 2026 results, with revenue above the estimate and adjusted EPS below it. Revenue was $259.9 million, up 61% from a year earlier, above the $245.5 million estimate, and adjusted EPS was $0.35, down 86% from a year earlier, below the $0.37 estimate.

Shares rose 7.0% in premarket trading as of 7:05 a.m. ET, to $64.00 from a $59.83 close.

Q3 2026 scorecard

By our calculation, revenue was $14.5 million above the estimate and adjusted EPS was $0.02 below it. The QoQ column compares with the previous quarter's revenue of $240.3 million and adjusted EPS of $0.05. The YoY column compares with $161.7 million and $2.43 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 2 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 4 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $161.7 million, $192.6 million, $204.9 million, $240.3 million and $259.9 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.45 and revenue of $269.5 million next quarter, based on 3 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 61% increase to $259.9 million.
• Estimate record. Whether TG Therapeutics returns to beating EPS estimates, which it did in 2 of its last 8 reports.
• Related coverage. See our reports on Fervo Energy, Select Water Solutions, Ionis Pharmaceuticals and Affiliated Managers.

Sources: Results are from TG Therapeutics's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from TG Therapeutics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.